<b>Gapping up</b><br/><b>In reaction to strong earnings/guidance:</b> LEJU +19.5%, FRSH +17%, WIX +10.1%, AEZS +9.2%, ZQK +8.8%, TENX +6.1%, EJ +4.7%, ENTL +4.2%, BONE +4%, CPXX +2.9%, CBRX +2.8%, ORCL +2.4%, NVGS +1.4%, MCUR +0.8%<br/><br/><b>M&A news: </b>VTSS +38% (Microsemi (MSCC) to acquire co for $5.28 per share), RXDX +27% (Ignyta and Teva announce acquisition by Ignyta of four oncology R&D assets from Teva in exchange for 1.5 mln shares (6%) of Ignyta's common stock), TWX +1.4% (Bloomberg discusses future of CBS, media M&A; CEO Moonves held talks with TWX CEO Bewkes last year, but he wasn't interested); MSCC +3.4% (VTSS merger and guidance)<br/><br/><b>Select oil/gas related names showing strength:</b> SDRL +1.7%, E +1.6%, RIG +1.4%, RDS.A +1.2%, STO +0.9%<br/><br/><b>Other news:</b> NVGN +40.9% (confirms that one of its oncology pipeline drug candidates, Anisina (ATM-3507), has achieved a major milestone in its development), RTRX +31.9% (confirms that the FDA has approved Cholbam capsules), VRML +30.1% (disclosed that on March 11, 2015, it entered into three agreements with Quest Diagnostics Incorporated (DGX); a Global Settlement Agreement and Mutual Release, a Testing and Services Agreement and a Non-Exclusive License Agreement ), MTL +21.4% (attributed to report that co and VTB are discussing debt restructuring), ATNM +12.2% (announces new data from ongoing Phase 1/2 trial of Actimab-A), AKRX +7.4% (announces filing of 10-K for year ended December 31, 2014; in addition to second and third quarter 2014 financial statements), NETE +6.9% (will acquire PayOnline), HLF +6% (seeing reports that co has received a favorable court ruling), SNE +4.7% (cont strength following yday's guidance), CANF +4.1% (completed the development of a commercial predictive biomarker blood test kit for the A3 adenosine receptor), JBL +3.7% (likely related to VTSS/MSCC merger), CRH +2.7% (may be related to Holcim / Lafarge news), VRTX +2.3% (receives U.S. FDA approval of KALYDECO for children with Cystic Fibrosis), HUBS +1.9% (prices 4,114,486 common shares at a price to the public of $37.00 per share), ACOR +1.9% (favorable commentary on Tuesday's Mad Money), MU +1.7% (hearing Samsung (SSNLF) to delay DRAM orders, positive for MU pricing environment), CIM +1.6% (announced that the Board has approved a reverse stock split of Chimera's outstanding shares of common stock at a ratio of 1-for-5; increased quarterly dividend to $0.096/share from $0.09/share), AMCC +1.4% (likely related to VTSS/MSCC merger)<br/><br/><b>Analyst comments: </b>MNRO +3.5% (upgraded to Buy from Neutral at Sun Trust Rbsn Humphrey), GNCA +2.5% (initiated with a Overweight at Piper Jaffray), P +2.4% (upgraded to Buy from Fair Value at CRT Capital)<br/><br/><b>Gapping down</b><br/><b>In reaction to disappointing earnings/guidance</b>: FPRX -7.2%, ADBE -4.5%, MTZ -3.6%, STLD -3.1%, OXGN -2.9%, EKSO -1.5%, ATU -1.2%, FOMX -1%, FDX -0.9%<br/><br/><b>M&A news:</b> BGC -3.8% (Reuters reported after hours Prysmian (PRYMF) spokesperson denying speculation in talks with General Cable; also downgraded to Hold from Buy at BB&T Capital Mkts), BBX -2.1% (BBX Capital Issues Statement Regarding BFC Financial Corporation Announcement of Cash Tender Offer for Shares of BBX Capital Class A Common Stock; Special Committee expects to retain a financial advisor and has retained Hogan Lovells US LLP as its legal advisor)<br/><br/><b>Select metals/mining stocks trading lower:</b> CLF -7.9%, MT -2.2%, RIO -2%, FCX -1.6%<br/><br/><b>Other news</b>: WG -30.1% (announces that it is filing a Form 12b-25 Notification of Late Filing with the SEC with regard to its Annual Report on Form 10-K), NKTR -14.7% (Nektar Therapeutics: Etirinotecan Pegol (NKTR-102) Prolonged Median Overall Survival by 2.1 Months versus Active Control in Patients with Advanced Breast Cancer in Phase 3 Study; Trial Did Not Achieve Statistical Significance ), NBG -12.3% (cont uncertainty in Greece), RSPP -5.6% (prices 5,000,000 shares of its common stock by the Company and 4,000,000 shares of its common stock by certain of the Company's stockholders at $25.80 per share), CYTX -5.3% (entered into Amendment One to the Securities Purchase Agreement between it and certain institutional investors dated October 8, 2015), ANTH -3.4% (announces proposed public offering of common stock; size and price details not disclosed ), SD -3.2% (cont weakness), CRR -3.1% (cuts quarterly dividend by 70% to $0.10/share, down from $0.33/share), ESI -2.5% (filed to delay FY14 Form 10-K), JKS -2.3% (unfavorable commentary on Tuesday's Mad Money; also has signed a strategic project development agreement with China Development Bank Leasing), ESPR -1.6% (following yesterday's 22 pt move higher), APP -1.3% (files to delay FY14 Form 10-K due to ongoing discussions with Standard General regarding revolving credit facility), BABA -1.2% (IPO lock-up exprires today), QGEN -1.2% (modest weakness following recent advance), NPO -0.9% (recently purchased for cash ~$21.3 mln in aggregate principal amount of its 3.9375% Convertible Senior Debentures due 2015 in a privately negotiated transaction)<br/><br/><b>Analyst comments: </b>NAV -3.4% (downgraded to Underweight from Equal-Weight at Morgan Stanley), USG -2.4% (downgraded to Neutral from Outperform at Robert W. Baird), IRBT -2.1% (downgraded to Outperform from Strong Buy at Raymond James), FLIR -1.5% (downgraded to Outperform from Strong Buy at Raymond James), RYI -1.5% (downgraded to Neutral from Overweight at JP Morgan), STJ -1% (downgraded to Market Perform from Outperform at Wells Fargo), ING -1% (removed from Alpha List at Berenberg), MELI -0.8% (downgraded to Neutral from Overweight at JP Morgan)<br/><br/>Allikas: Briefing.com